Evidence map›Paper›PMID 38565741›Full record

ArticleScience China. Life sciences2024

Cytokines-activated nuclear IKKα-FAT10 pathway induces breast cancer tamoxifen-resistance.

Xueyan Chen, Weilin Wu, Ji-Hak Jeong, Matjaz Rokavec, Rui Wei, Shaolong Feng, Werner Schroth, Hiltrud Brauch, Shangwei Zhong, Jun-Li Luo

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. PAX Family, Master Regulator in Cancer.Diagnostics (Basel, Switzerland) · 2025
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Xueyan Chen *Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Weilin Wu *Department of Molecular Medicine, The Scripps Research Institute, Jupiter, 33458, USA.
Ji-Hak JeongDepartment of Molecular Medicine, The Scripps Research Institute, Jupiter, 33458, USA.
Matjaz RokavecDepartment of Molecular Medicine, The Scripps Research Institute, Jupiter, 33458, USA.
Rui WeiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Shaolong FengDepartment of Molecular Medicine, The Scripps Research Institute, Jupiter, 33458, USA.
Werner SchrothDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, 70376, Germany.
Hiltrud BrauchDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, 70376, Germany.
Shangwei ZhongDepartment of Molecular Medicine, The Scripps Research Institute, Jupiter, 33458, USA. swzhong@usc.edu.cn.
Jun-Li LuoDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, China. jlluo@usc.edu.cn.
Scripps Research Institute · USCentral South University · CNDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DEUniversity of Tübingen · DEXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endocrine therapy that blocks estrogen signaling is the most effective treatment for patients with estrogen receptor positive (ER

Indexed as

Breast NeoplasmsDrug Resistance, NeoplasmI-kappa B KinaseSignal TransductionTamoxifenAnimalsAntineoplastic Agents, HormonalCell Line, TumorCytokinesFemaleGene Expression Regulation, NeoplasticHumansMCF-7 CellsTumor Suppressor Protein p53UbiquitinsAntineoplastic Agents, HormonalCHUK protein, humanCytokinesI-kappa B KinaseTamoxifenTumor Suppressor Protein p53UBD protein, humanUbiquitinsbreast cancerFAT10lymphotoxinnuclear IKKαnuclear IKKα-FAT0 pathwayPax5Tam-resistance

Identifiers

PMID38565741
OpenAlexW4393867821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.